Table 3 Multivariate analysis for TTNT.

From: Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin

Factors

 

Multivariate analysis

Hazard ratio

95% CI

p-value

Type of treatment regimen

ERd

1

 

0.202

EPd

0.694

0.395–1.217

 

White blood cell counts

< 3500/μl

1

 

0.776

≥ 3500/μl

0.935

0.591–1.481

 

Lymphocyte counts

< 1400/μl

1

 

0.009

≥ 1400/μl

0.491

0.289–0.835

 

κ/λ ratio

0.1–10

1

 

0.05

< 0.1, ≥ 10

1.628

0.999–2.653

 

B2MG

< 5.5 mg/L

1

 

0.008

≥ 5.5 mg/L

2.09

1.212–3.605

 

Prior regimen numbers

< 4

1

 

0.088

≥ 4

1.718

0.923–3.198

 

Prior use of daratumumab

No

1

 

< 0.001

Yes

3.009

1.815–4.989

 
  1. Multivariate analyses against TTNT in MM patients treated with elotuzumab were performed using the factors that showed p < 0.1 in univariate analysis. The Cox proportional hazard model was used to calculate the hazard ratio for each variable; the 95% CI and p-value are shown.
  2. TTNT, CI, ERd, EPd and B2MG. TTNT: time to next treatment; CI: confidence interval; ERd: elotuzumab, lenalidomide and dexamethasone regimen; EPd: elotuzumab, pomalidomide and dexamethasone regimen; B2MG: β2 microglobulin.
Back to article page